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Abstract
Background: WW domain containing oxidoreductase (WWOX) gene was cloned in 2000; alteration has been seen
in many cancer cells. It acts as a tumor suppresser by blocking cell growth and causing apoptosis. WWOX protein
showed different expression of mice brain and spinal cord, for which deletion causes seizure and early death.
Case presentation: Clinical and molecular characteristics of a consanguineous family show a homozygous
mutation of WWOX gene at specific bases, causing a debilitating syndrome characterized by growth retardation,
intractable epilepsy, intellectual disability, and early death.
Using Whole Exome Sequencing (WES), a novel homozygous mutation in the WWOX gene is identified in
a consanguineous Arab family from Qatar with two daughters who presented with intractable seizure and
developmental delay.
Conclusion: The study presents the importance of human WWOX gene for brain development and the
association between gene mutation and epileptic encephalopathy. It also highlights the power of WES
particularly in clinically challenging cases.
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Background
WWOX gene spans a common fragile site FRA16D [1]
Alteration of this gene has been associated with tumori-
genesis [2] The expression of WWOX protein in the de-
veloping brain and spinal cord in the embryo and
newborn mice together with the histological findings are
showing a convincing evidence of its role in neural de-
velopment [3]. This study identifies two siblings with
novel WWOX gene mutation who presented for evalu-
ation of epileptic encephalopathy. It highlights that the
importance of whole exome sequencing in identifying
causal mutations in challenging medical conditions [4].
Case presentation
Patients
The family came to medical attention because the eldest
daughter presented with intractable seizure and develop-
mental delay. A consanguineous family (Fig. 1a) with 4
children; 2 healthy boys, and the 2 affected girls. Informed
consent was taken from the parents and obtained IRB
(institutional review board) approval from the Ethics com-
mittee in the Medical Research Center at Hamad Medical
Corporation.
Patient 1
The proband is a 7-year-old girl, born at term after an
uneventful pregnancy, admitted to the Neonatal Inten-
sive Care Unit with transient tachypnea for one week.
At 7 weeks of age, she was admitted to the hospital
with abnormal movements. The abnormal movements
described as unilateral alternating jerking of upper and
lower limbs, which subsequently became bilateral. The
movements were associated with eye gazing and blink-
ing lasting for short periods and recurring up to 20–30
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times per day. A video recording indicated typical myo-
clonic jerks. A trial of antiepileptic medications
including phenobarbitone, clonazepam, phenytoin and
levetiracetam, all failed to control the seizures. Devel-
opmentally, she had no eye contact and poor head
control. Examination at 6 month of age, weight was 8.9
Kg (+1.43 SD), length 64 cm (+1.08 SD) and OFC
43 cm (+0.37SD). She had no dysmorphic features; gen-
eralized hypertonia. Eye examination showed both pu-
pils were mid-dilated but reactive, however she was not
blinking to strong light. There was no lens or corneal
opacity. Fundoscopy showed bilateral optic discs’ pallor
with normal retina. At 9 months of age, she had signifi-
cant feeding difficulties necessitating nasogastric tube
insertion initially, followed by gastrostomy tube feeding.
At 2 years of age, she had progressive respiratory insuf-
ficiency requiring CPAP through tracheostomy, which
eventually needed to be changed to mechanical ventila-
tion. At the age of 4 years, there were poor head and trunk
support with minimal limb movements, as well as pro-
gressive muscular weakness, hypertonia, and brisk deep
tendon reflexes bilaterally. Currently, she is severely
impaired with intractable seizure and in a vegetative state.
Metabolic investigations including ammonia, lac-
tate, plasma amino acids, urine organic acids, carni-
tine profile, plasma very long chain fatty acids,
lysosomal enzymes studies, and CSF neurotransmit-
ters, all were normal. Muscle and skin biopsies for
mitochondrial studies were performed at another
center and reported as normal. EEG showed frequent
epileptic activity and abnormal background. Electro-
retinogram was normal, but visual evoked potential
was delayed. Brain MRI showed progressive demye-
lination and atrophy of both frontal and temporal
areas (Fig. 2a, b and c).
Patient 2
The younger sister of the proband is a 20-month-old girl
who was born after uneventful pregnancy and delivery.
She presented with abnormal movement at the age of
7 weeks, in the form of focal tonic contraction on the
right side with deviation of the mouth lasting from few
seconds to 10 min associated with lip smacking and
drooling. Antiepileptic medications including phenobar-
bitone, clobazam and topiramate showed partial re-
sponse. The seizure attacks progressed for which she
needed repeated hospital admissions. Developmentally,
she could not roll, weak grasp for object and poor eye
contact. Examination at 6 months of age, weight was
5.95 (−2.2 SD) length was 63.5 cm (−0.99 SD) and head
circumference was 42 cm (0.16 SD). She had no dys-
morphic features, no facial asymmetry. There was poor
head control with increased tone and brisk reflexes in
all limbs. At 8 months, she was admitted with acute
bronchiolitis needing PICU admission for non-invasive
ventilation; she had swallowing assessment for which
she was started on nasogastric tube feeding. Currently,
she is having severe psychomotor retardation and epi-
leptic encephalopathy. Brain MRI showed progressive
demyelination and atrophy of both frontal and tem-
poral areas. (Fig. 2a, b).
At 16-month of age, she was admitted to PICU due to
fever, acute respiratory failure and intractable Epilepsy.
During this admission, she was seen by Gastroenterology
team due to history of choking, gagging and aspiration.
She had a G-tube and is currently entirely fed through a
G-tube and nothing by mouth. In addition, she also seen
by Orthopedics due to her healing right proximal hu-
merus fracture and was noted to have mild neurogenic
scoliosis. On exam, length was 85.1 cm, weight was
15.2 kg and head circumference was 48.5 cm. She had
Fig. 1 Family pedigree showing the consanguineous parents with affected sisters (black arrow) and unaffected brothers
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contractures of all 4 limbs. She was alert, but not inter-
active, sitting in a wheelchair. Strength was 2 in all ex-
tremities with normal muscle bulk and tone. Deep tendon
reflexes were 2+ in the upper and lower extremities, and 3
+ reflexes in the ankles with sustained clonus at the left
and right. She had positive Babinski bilaterally.
Fig. 2 a Patient 1 initial MRI at age 9 weeks showing poor myelination with absent dark T2 and bright T1 signal in white mater tracts,
marked widening of the Sylvian fissure (black arrow), moderate widening of the frontal sulci (white arrow) and mild ventricular dilatation
in favor of frontal and temporal cortical atrophy. Marked symmetrical thinning of the corpus callosum (arrow heads). b Patient (1) follow
up MRI at the age of 23 weeks showing significant progress in myelin loss with absent white mater myelination on T2 and marked
progression in the frontal and temporal cortical atrophy. There is marked reduction of the size and deformity of the hippocampus (black
arrow) with loss of its normal ram horn like whirled appearance. There is focal restricted diffusion along the cortico-spinal tract in the
brain stem (white arrow)
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She had plasma lactate, T4, TSH, AST, ALT, vitamin
D, urine for organic acids, plasma and urine amino
acids, CGH array, all were normal. EEG showed electro-
clinical generalized tonic seizure, multiple myoclonic
generalized seizures, multifocal spikes, generalized fast
spikes, continuous generalized slowing, lack of normal
sleep elements, and diffuse encephalopathy. A 24-h EEG
showed 8 generalized spasms or tonic seizures per hour
with multi-focal spikes while awake, and discontinuity of
the background during sleep.
Exome sequencing
Samples from the two patients were sent for WES and
were done at GeneDx, MD USA (www.genedx.com), a
commercial laboratory offering WES as a diagnostic ser-
vice. Briefly, genomic DNA was extracted from whole
blood. Exome sequencing was performed on exon targets
isolated by capture using the Agilent SureSelect Human
All Exon V4 (50 Mb) kit (Agilent Technologies, Santa
Clara, CA) and was sequenced using the IlluminaHiSeq
2500 sequencing system with 100-bp paired-end reads
(Illumina, San Diego, CA). The identified pathogenic
variants were validated and were confirmed by Sanger
sequencing. Whole-exome sequencing of patient 1 &
2 showed a novel homozygous W44X mutation
[p.Trp44Stop (TGG > TAG): c.131 G > A in exon 2] in
the WWOX gene. Segregation study showed both parents
are heterozygous W44X mutation. The W44X pathogenic
mutation in the WWOX gene is predicted to cause loss of
normal protein function either through protein truncation
or nonsense-mediated mRNA decay. This mutation
was not observed in approximately 6000 individuals
of European and African American ancestry in the
NHLBI Exome Sequencing Project, indicating it is not
a common benign variant in these populations.
Discussion
WWOX gene is situated in the second most common
fragile site of breakage known as FRA16D, which con-
tains nine exons encodes a 414 amino acids protein [1]
It contains two WW domains on the NH2 terminus of
the protein and an SDR central domain with a chromo-
somal area characterized by a very high incidence of
allelic loss and chromosomal rearrangements [1].
WWOX gene has been identified in many cancer cells,
for example upregulation was found during prostatic
and breast cancer progression from hyperplasia to me-
tastasis [2] Targeted deletion of Wwox in mice has been
found to cause growth retardation and early postnatal
death [5]. Understanding the role of Wwox in the brain
development showed that loss of function of Wwox gene
causes seizure in rats [3] McDonald CB et al. [6] showed
that the replacement of R25 and W44 within the WW1
domain with E66 and Y85, respectively, at corresponding
structurally equivalent positions within the WW2 domain
accounts for the lack of binding of the WW2 to PPXY (X
is any amino acid) motifs within WBP1 (WW binding
protein 1) and WBP2 (WW binding protein 2) adaptors.
The Y residue of the PPXY WW-binding motif is a poten-
tial target of tyrosine phosphorylation. Indeed, tyrosine
phosphorylation of this motif has been shown to regulate
the interaction between several WW proteins and their
interacting proteins [7]. These interactions could be a
channel in understanding of the disease pathophysiology.
Autosomal recessive WWOX gene mutation has been
identified in several families with a variable neurodeve-
lopmental phenotypic spectrum [8–12]. In two families,
early death with microcephaly, epileptic seizures, growth
retardation and eye abnormalities (retinopathy and optic
atrophy) result from homozygous early premature ter-
mination codons in WWOX gene [9, 10]. In two other
families, cerebellar ataxia with epilepsy and mental
retardation are consequences of missense mutation in
the WWOX gene [10].
In 2015, Mignot et al. [11] reported seven families with
WWOX-related encephalopathies and has concluded a
genotype-phenotype correlation with variable phenotypic
presentation. In four patients with two predicted null
alleles, the clinical manifestations include severe psycho-
motor retardation, early intractable epilepsy, poor eye
contact with retinal degeneration, secondary microceph-
aly, abnormal brain MRI and premature death. The other
group of patients due to hypomorphic alleles showed a
spinocerebellar ataxia type 12 phenotype that include
cerebellar limb and gait ataxia, delayed psychomotor de-
velopment, spasticity, hyporeflexia, and onset of seizures
between 9 and 12 months of age. Our cases fit well with
WOREE syndrome (WWOX-related epileptic encephal-
opathy). It was first described in four families in Mignot et
al [11] of which three described as a WOREE syndrome
having a similar presentation to the two families reported
by Abdel-Salam et al. [8] and Ben Salem et al. [9] with
early termination codons [8, 9, 11]. The most recent fam-
ily reported had one case with a prenatal diagnosis of
WOREE syndrome [12].
Epileptic encephalopathies have wide-range of disor-
ders characterized by epilepsy with permanent detrimen-
tal effect on the developing brain [13]. Therefore, it is
customary that patients with epileptic encephalopathy
usually undergo a vast array of biochemical and molecu-
lar tests leading to an expensive workup. However, the
diagnosis often remains elusive despite extensive testing
which prolong the length of the diagnostic odyssey [14].
Hence, whole-exome sequencing is a powerful diagnostic
tool that has been used recently to assist in the diagnosis
of many monogenic neurometabolic disorders.
We have identified a consanguineous Qatari family
with a novel W44X mutation in the WWOX gene. This
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mutation is predicted to cause loss of normal protein
function either through protein truncation or nonsense-
mediated mRNA decay. To the best of our knowledge
there are ten families reported including our family,
six of which are consanguineous Middle Eastern
families [8–10, 12]. The other four families are non-
consanguineous [11]. All reported cases presented with
progressive severe epilepsy, psychomotor retardation,
and brain abnormalities (Table 1).
Conclusion
This family exemplifies the challenges in establishing an
accurate diagnosis in patients presented with non-
specific epileptic encephalopathy and we recommend
performing WES as a first line test to reach the final
diagnosis particularly in populations with high rates of
consanguinity. Furthermore, the role of WWOX gene in
brain development is crucial and the relationship between
epileptic encephalopathy with gene mutation warrant fur-
ther studies to determine the exact pathophysiology.
Abbreviations
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Table 1 Clinical phenotypes in patients with Homozygous WWOX gene mutation
Our study Mylene valduga
et al. [12]a
Ben Salem et al. [9] Mignot et al. [11] Abdel-Salam et al. [8] Mallaret et al. [10]
No of Families 1 1 1 4 1 2
No of pts 2 2 1 5 1 4
Gender 2F 1F-1M 1M 4F-1M F 3F-1M
Consanguinity + + + - + +
Ethnicity Qatari Turkish Emirati NA Egyptian Saudi-Palestinian
Acquired
microcephaly
- + + (3/5 - ) (2/5 +)b + NA
Neonatal
hypotonia
- - + + + NA
Psychomotor delay + + + + + +
Cerebellar ataxia - - - - - +
Spasticity + + + 3/5 (-), 2/5 (+) + -





+ + + 3+, 2- + +
Age of onset of
epilepsy
2 month 3 month 2 weeks Between <2m and 5m Yes (2 month) (9–12 m)
Seizure type Myoclonic
seizure




















Brain atrophy Posterior white matter
hyperintensities
Premature death - + - 2 (+)-3(-) + -
F female, M male, No number, pts patients, DTR deep tendon reflexes, NA not applicable
aThe case diagnosed prenatally was not included in the table as the comparison points are not applicable
b3/ 5 cases did not have microcephaly, while 2/5 cases have microcephaly
c2/5 spastic and 3/5 normal tone. The deep tendon reflex was normal in 3/5 while exaggerated in 2/5
d2 cases had normal MRI
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